Brainsway has reported additional interim results of a clinical trial being conducted at the Ichilov Medical Center in Israel to evaluate the efficacy of a deep transcranial magnetic stimulation (TMS) system in the treatment of Alzheimer’s disease.

The interim study included 24 patients who were divided into three groups: a sham stimulation control group, a low-frequency treatment group and a high-frequency treatment group.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Each subject received treatment over eight weeks, and the efficacy of the treatment was evaluated both during the trial and over the course of the subsequent eight-week period.

Treatment using deep TMS was well-tolerated by all subjects, with no side-effects.

Efficacy was evaluated using the Alzheimer’s Disease Assessment Scale – Cognitive test and a quality-of-life scale.

The results suggest that high-frequency treatment leads to improvement on Alzheimer’s disease assessment scales, whereas low-frequency and sham treatment do not.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now